MYOM2 and plasma cell myeloma: In 2020, the Czech Myeloma Group developed a risk stratification model that identified a group of ultra-high-risk patients with SMM who were estimated to have an 80% chance of progression to active MM within 2 years using serum parameters (FLC ratio >30, immunoparesis, and serum M protein ≥2.3 g/dl) [12].